Akademik Veri Yönetim Sistemi
Turkiye Klinikleri Cardiovascular Sciences, cilt.32, sa.2, ss.75-83, 2020 (Scopus, TRDizin)
Objective: Apolipoprotein M (ApoM) is a novel antiatherosclerotic protein which is present predominantly (~5%) in high density lipoprotein (HDL) and in trace amounts (<2%) in low density lipoprotein (LDL). In recent studies, it is reported that ApoM which is known to play important role in HDL metabolism via revers cholesterol transport, has protective effects against LDL oxidation and atherosclerosis. However, clinical studies revealing the association between ApoM and diseases are very limited. Therefore, we aimed to investigate the relationship between serum ApoM and lipid levels in restenosis patients and healthy controls on the basis of its effects on cholesterol metabolism. This is the first study revealing the association between serum ApoM and lipid levels in restenosis patients. Material and Methods: Thirty-six restenosis patients and 42 healthy controls were included in our study. Serum ApoM levels were measured by ELISA method. Results: The serum ApoM (p=0.022), total-cholesterol (Total-C) (p=0.008) and HDL-cholesterol (HDL-C) (p<0.001) levels of patients were lower than the control group, while fasting blood glucose, HbA1c (p<0.001) and triglyceride (TG) (p=0.002) levels were higher. In addition, higher risk threshold values for serum TG (≥150 mg/dL) and LDL-cholesterol (LDL-C) (≥130 mg/dL) in the restenosis group were detected to be associated with higher ApoM levels in the restenosis patient group (p=0.038 and p=0.041, respectively). However, this relationship was not observed in control group (p>0.05). Conclusion: Serum ApoM level exhibited a significant, positive correlation not only with the HDL-C level, but also with the Total-C, TG and LDL-C levels in patients with restenosis. These results indicated that the serum ApoM levels may affects the serum TG and cholesterol levels so that contributes to the development of restenosis.